» Articles » PMID: 16395099

Usefulness of C-reactive Protein to Define Pneumococcal Conjugate Vaccine Efficacy in the Prevention of Pneumonia

Overview
Specialty Pediatrics
Date 2006 Jan 6
PMID 16395099
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives And Methods: This study explored whether C-reactive protein (CRP) and/or procalcitonin levels were useful to measure vaccine efficacy (VE) and impact against the burden of pneumonia of a 9-valent pneumococcal conjugate vaccine (PCV), compared with chest radiograph-confirmed alveolar consolidation (CXR-AC) as an outcome. Sera obtained from children participating in a phase 3 PCV efficacy trial who were hospitalized for treatment of clinically diagnosed lower respiratory tract infection (C-LRTI) were retrospectively analyzed for CRP and procalcitonin measurements.

Results: For non-human immunodeficiency virus (HIV)-infected children, the VE estimates for C-LRTI with CRP levels of > or =40 mg/dL (VE 26.3%; P = 0.003) or CRP levels of > or =120 mg/dL (VE 41.0%; P = 0.003) were 1.7-fold (P = 0.002) and 2.7-fold (P < 0.0001) greater, respectively, than that for CXR-AC (VE 15.1%; P= 0.15). The sensitivity of CXR-AC as an outcome to detect the burden of pneumonia prevented by PCV was 44% (95% confidence interval, 36-55%) in comparison with C-LRTI with CRP levels of > or =40 mg/dL and 73% (95% confidence interval, 58-92%) in comparison with C-LRTI with CRP levels of > or =120 mg/dL. CRP also helped to measure the PCV efficacy for children with C-LRTI but the absence of CXR-AC, for whom the outcome of C-LRTI with CRP levels of > or =40 mg/dL (VE 31.5%; P = 0.007) increased the VE estimate 19.8-fold (P < 0.0001) in comparison with C-LRTI alone (VE 1.6%; P = 0.78) and 3.2-fold (P = 0.005) in comparison with WHO-defined severe pneumonia (VE 10.0%; P = 0.17). Although there was a significant correlation between CRP and procalcitonin levels (Spearman's rho = 0.45; P < 0.0001), the use of procalcitonin levels did not improve either the specificity or sensitivity of measuring the effect of PCV against pneumonia for non-HIV-infected children. The observations were similar for HIV-infected children.

Conclusions: CRP levels of > or =40 mg/dL provide a better measure than chest radiographs to assess the effect of PCV in preventing pneumonia.

Citing Articles

The radiological diagnosis of pneumonia in children.

OGrady K, Torzillo P, Frawley K, Chang A Pneumonia (Nathan). 2019; 5(Suppl 1):38-51.

PMID: 31641573 PMC: 5922330. DOI: 10.15172/pneu.2014.5/482.


Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group.

Goodman D, Crocker M, Pervaiz F, McCollum E, Steenland K, Simkovich S Lancet Respir Med. 2019; 7(12):1068-1083.

PMID: 31591066 PMC: 7164819. DOI: 10.1016/S2213-2600(19)30249-8.


Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveys: a study protocol for a prospective observational study and lessons learned.

La Vincente S, Von Mollendorf C, Ulziibayar M, Satzke C, Dashtseren L, Fox K BMC Public Health. 2019; 19(1):333.

PMID: 30898094 PMC: 6429832. DOI: 10.1186/s12889-019-6639-y.


Community-acquired pneumonia in children - a changing spectrum of disease.

Le Roux D, Zar H Pediatr Radiol. 2017; 47(11):1392-1398.

PMID: 29043417 PMC: 5608782. DOI: 10.1007/s00247-017-3827-8.


Higher risk for incident heart failure and cardiovascular mortality among community-dwelling octogenarians without pneumococcal vaccination.

Ahmed M, Patel K, Fonarow G, Morgan C, Butler J, Bittner V ESC Heart Fail. 2016; 3(1):11-17.

PMID: 27668089 PMC: 5019269. DOI: 10.1002/ehf2.12056.